Whalesbook Logo

Whalesbook

  • Home
  • About Us
  • Contact Us
  • News

Child Deaths in India Linked to Adulterated Cough Syrup, Exposing Regulatory Weaknesses

Healthcare/Biotech

|

Updated on 03 Nov 2025, 11:44 am

Whalesbook Logo

Reviewed By

Aditi Singh | Whalesbook News Team

Short Description :

Over 24 children under five have died in Madhya Pradesh due to contaminated cough syrup found to contain diethylene glycol (DEG). The World Health Organization has issued a global alert for the specific batches, manufactured in India. This incident highlights severe systemic failures in India's pharmaceutical regulatory oversight, weak quality control, and outdated laws, impacting public health and the country's reputation as a medicine exporter.
Child Deaths in India Linked to Adulterated Cough Syrup, Exposing Regulatory Weaknesses

▶

Detailed Coverage :

Tragically, at least 24 children, all under five years old, have died in Madhya Pradesh over the past month after consuming adulterated cough syrup. The deaths are primarily linked to specific batches of three oral liquid medicines: Coldrif, Respifresh TR, and ReLife, which were found to contain diethylene glycol (DEG), a toxic industrial solvent. The Central Drugs Standard Control Organisation (CDSCO) confirmed the contamination but stated these batches were not exported. However, the World Health Organization (WHO) has issued a global alert, urging countries to monitor for these products.

This incident echoes similar tragedies in The Gambia, Uzbekistan, and Cameroon, where children died from Indian-made cough syrups. Experts point to systemic failures in India's pharmaceutical regulatory oversight, weak quality control, and outdated laws like the Drugs and Cosmetics Act of 1940. The infrastructure for testing is underdeveloped, and there is poor coordination between central and state drug regulators. Contract manufacturing practices and insufficient pharmacovigilance further compound these issues.

Impact: This news significantly impacts the Indian pharmaceutical sector, investor confidence in drug safety and manufacturing standards, and the country's international reputation as a reliable medicine exporter. It also highlights a critical public health and governance issue. Rating: 8/10.

Difficult Terms: Diethylene Glycol (DEG): A toxic industrial solvent that can cause severe kidney damage and death when ingested. Adulterated: Mixed with a foreign or inferior substance, often fraudulently. Regulatory Oversight: The supervision and control of an industry or activity by a regulatory authority. Pharmaceuticals: Drugs or medicines; the industry involved in their production and sale. Contract Manufacturing: When a company hires another company to produce its products, often to save costs. Pharmacovigilance: The science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or any other medicine-related problem.

More from Healthcare/Biotech


Latest News

Suzuki and Honda aren’t sure India is ready for small EVs. Here’s why.

Auto

Suzuki and Honda aren’t sure India is ready for small EVs. Here’s why.

Stocks to buy: Raja Venkatraman's top picks for 4 November

Brokerage Reports

Stocks to buy: Raja Venkatraman's top picks for 4 November

Quantum Mutual Fund stages a comeback with a new CEO and revamped strategies; eyes sustainable growth

Mutual Funds

Quantum Mutual Fund stages a comeback with a new CEO and revamped strategies; eyes sustainable growth

Why Pine Labs’ head believes Ebitda is a better measure of the company’s value

Tech

Why Pine Labs’ head believes Ebitda is a better measure of the company’s value

SEBI is forcing a nifty bank shake-up: Are PNB and BoB the new ‘must-owns’?

Banking/Finance

SEBI is forcing a nifty bank shake-up: Are PNB and BoB the new ‘must-owns’?

India’s Warren Buffett just made 2 rare moves: What he’s buying (and selling)

Industrial Goods/Services

India’s Warren Buffett just made 2 rare moves: What he’s buying (and selling)


Renewables Sector

Brookfield lines up $12 bn for green energy in Andhra as it eyes $100 bn India expansion by 2030

Renewables

Brookfield lines up $12 bn for green energy in Andhra as it eyes $100 bn India expansion by 2030


Energy Sector

India's green power pipeline had become clogged. A mega clean-up is on cards.

Energy

India's green power pipeline had become clogged. A mega clean-up is on cards.

More from Healthcare/Biotech


Latest News

Suzuki and Honda aren’t sure India is ready for small EVs. Here’s why.

Suzuki and Honda aren’t sure India is ready for small EVs. Here’s why.

Stocks to buy: Raja Venkatraman's top picks for 4 November

Stocks to buy: Raja Venkatraman's top picks for 4 November

Quantum Mutual Fund stages a comeback with a new CEO and revamped strategies; eyes sustainable growth

Quantum Mutual Fund stages a comeback with a new CEO and revamped strategies; eyes sustainable growth

Why Pine Labs’ head believes Ebitda is a better measure of the company’s value

Why Pine Labs’ head believes Ebitda is a better measure of the company’s value

SEBI is forcing a nifty bank shake-up: Are PNB and BoB the new ‘must-owns’?

SEBI is forcing a nifty bank shake-up: Are PNB and BoB the new ‘must-owns’?

India’s Warren Buffett just made 2 rare moves: What he’s buying (and selling)

India’s Warren Buffett just made 2 rare moves: What he’s buying (and selling)


Renewables Sector

Brookfield lines up $12 bn for green energy in Andhra as it eyes $100 bn India expansion by 2030

Brookfield lines up $12 bn for green energy in Andhra as it eyes $100 bn India expansion by 2030


Energy Sector

India's green power pipeline had become clogged. A mega clean-up is on cards.

India's green power pipeline had become clogged. A mega clean-up is on cards.